What is Sanara's gross profit margin?

What were the key takeaways from Sanara’s earnings call?

Did Sanara beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Sanara next quarter?

What is the revenue and EPS growth rate for Sanara year over year?

What were the key takeaways from Sanara's earnings call?

What is Sanara's latest dividend and current dividend yield?

What guidance did Sanara's management provide for the next earnings period?

- **Revenue record**: 2025 net revenue surpasses $100M for first time at $103.1M (+19% YoY).
- **Margin strength**: Gross margin expands to 93%, with $17M adjusted EBITDA and $6.8M cash from operations.
- **Distributor expansion**: 450+ distributors and 1,450+ healthcare facilities served, driving surgical market penetration.
- **2026 growth**: Guided for $116-121M net revenue (+13-17%), fueled by BIASURGE/Vizient deal and CellerateRX clinical/economic validation.

**【CEO Summary Section】**
- **Revenue milestone**: Full year 2025 net revenue reached $103.1 million, up 19% YoY, driven by soft tissue and bone fusion products.
- **Gross margin expansion**: Improved to 93% (up 200bps YoY) with $1.5M net loss reduction and $17M adjusted EBITDA.
- **Distributor network growth**: Ended 2025 with 450+ distributors (vs. 350+ in 2024), supporting 1,450+ healthcare facilities.
- **BIASURGE momentum**: Secured Vizient's Innovative Technology contract, offering access to 1,800+ facilities starting Q1 2026.
- **2026 guidance**: Net revenue target of $116-121 million (13-17% YoY growth), with focus on surgical market penetration.

**【CFO Financial Commentary】**
- **Q4 2025 results**: $27.5M net revenue (5% YoY), $25.7M gross profit (93% margin), $6.8M cash from operations.
- **Balance sheet**: $16.6M cash, $46M long-term debt as of Dec 31, 2025.
- **Cost management**: Reduced net loss to $1.1M vs. $0.9M net income YoY, driven by $1.8M non-cash IP impairment.
- **2026 outlook**: $116-121M net revenue, with investments in field sales and R&D to support growth.

**【Q&A Highlights】**
- **BIASURGE contract impact**: Vizient deal provides access to 1,800+ facilities, but growth will depend on facility-level adoption.
- **CellerateRX growth**: Economic study highlights cost-effectiveness, aligning with clinical evidence to drive adoption.
- **OsStic pipeline**: Expected U.S. launch in Q1 2027 as FDA Breakthrough Device for bone repair.

Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript

- **Strategic Shift**: Discontinued THP to focus on Surgical business, freeing $5.5-$6.5 million in 2025 for core growth.
- **Revenue Surge**: Q3 Surgical revenue $26.3 million (+22% YoY), trailing 12-month $102 million (+31% YoY), driven by soft tissue repair products.
- **Operational Efficiency**: 31% revenue growth with 157% EBITDA increase, enabled by flat headcount and distributor network expansion.
- **Future Growth**: Q4 2025 revenue expected +10-15% YoY (excluding one-time 2024 impact), with Surgical business targeting 10-20% annual growth.
- **Clinical Validation**: Published studies confirm CellerateRX efficacy in complex cases, supporting surgeon adoption.


**【CEO Summary Section】**
- **THP Discontinuation**: Announced cessation of Tissue Health Plus (THP) operations, with total cash investment in 2025 expected to be $5.5-$6.5 million. THP will be classified as discontinued operations, freeing resources for Surgical business.
- **Revenue Growth**: Q3 2025 Surgical net revenue $26.3 million (+22% YoY), driven by 24% increase in soft tissue repair products (CellerateRX, BIASURGE). Full-year trailing 12-month revenue $102 million (+31% YoY).
- **Commercial Strategy**: Expanded distributor network to 400+ (from 300+), sold into 1,200+ healthcare facilities (vs. 1,000+ prior year), and increased surgeon penetration in existing facilities. Focus on new specialties beyond spine/orthopedics.
- **Operational Highlights**: Published clinical evidence in high-impact journals demonstrating CellerateRX efficacy in complex cases. OsStic (periarticular fracture product) on track for U.S. launch Q1 2027, with BMI completing all regulatory milestones.

**【CFO Financial Commentary】**
- **Gross Profit**: Q3 2025 gross profit $24.5 million (+24% YoY), margin 93% of net revenue (vs. 91% prior year).
- **Operating Expenses**: SG&A $21.5 million (+14% YoY), driven by salesforce expansion and marketing. R&D $0.2 million (+31% YoY).
- **Net Income**: Net income from continuing ops $0.8 million ($0.09 EPS), vs. $0.2 million loss prior year. Adjusted EBITDA $4.9 million (+2.3 million YoY).
- **Cash Flow**: Q3 operating cash flow $2.2 million. Total cash $14.9 million, debt $45.1 million.

**【Q&A Key Highlights】**
- **Penetration Strategy**: Focus on educating surgeons on clinical/economic benefits of products. Distributor network and direct salesforce driving new facility adoption.
- **Operating Leverage**: Flat headcount (40 W-2 reps, 400 distributors) enabling 31% revenue growth with EBITDA up 157% YoY. Expect continued leverage as THP costs decline.
- **Growth Outlook**: Q4 2025 revenue expected to grow high single to low teens YoY (excluding $1.8 million one-time 2024 hurricane impact). Long-term Surgical business seen as 10-20% grower with improving margins.
- **THP Lessons**: Strategic review process confirmed limited partner interest, aligning with Board decision to focus on core Surgical business.


Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call Transcript

- **Surgical Segment Dominance**: 28% YoY revenue growth, driven by soft tissue and bone fusion products, with net income improving by $2.7 million.
- **THP Strategic Shift**: Reduced cash investment in H1 to $7.5 million, with H2 spending capped at $6.5 million. Strategic alternatives evaluation aims to maximize value.
- **Operational Efficiency**: Gross margin up 250bps to 93%, operating cash flow positive at $2.7 million in Q2.
- **Pipeline Momentum**: OsStic launch on track for Q1 2027, with THP pilot program validating technology platform functionality.

**【CEO Summary Section】**
- Surgical segment revenue grew 28% YoY to $25.8 million, driven by soft tissue products (28% YoY) and bone fusion products (25% YoY). Surgical segment net income improved by $2.7 million to $500,000, with adjusted EBITDA up 239% to $4.7 million.
- THP segment cash investment reduced to $7.5 million in H1 (vs. $7.5-$8.5 million guidance), with plans to limit H2 spending to $5.5-$6.5 million. Strategic alternatives for THP are being evaluated.
- Consolidated net loss narrowed 43% YoY, with adjusted EBITDA up 350% to $2.7 million. Operating cash flow improved to $2.7 million in Q2.

**【Seth Yon - Commercial Execution】**
- Distributor network expanded to 400+ partners (vs. 300+ last year), with focus on onboarding and training. New health care facilities served increased to 1,400+ (vs. 1,100+ prior year). Surgeon penetration grew, with adoption in plastics, general, and vascular specialties.
- BIASURGE sales doubled YoY, complementing CellerateRx Surgical in wound irrigation procedures. Approvals for BIASURGE expanded to 4,000+ facilities.

**【Sam Muppalla - THP Segment Update】**
- THP Copilot pilot program launched with a 6-state wound care provider group, integrating with EMR for home-based care. Platform functionality validated, with insights on EMR integration and user experience enhancements.
- THP technology showcased at industry conferences, with payer pilot discussions underway for Q4 launch. Strategic alternatives evaluation aims to maximize shareholder value.

**【Elizabeth Taylor - Financial Highlights】**
- Gross profit rose 32% YoY to $23.9 million, with gross margin improving 250bps to 93%. Operating expenses increased 14% to $23.9 million, driven by surgical sales growth and THP infrastructure costs.
- Net loss narrowed to $2 million (vs. $3.5 million YoY), with Surgical segment generating $2.5 million operating income. Cash balance of $17 million and $12.25 million borrowing capacity support growth initiatives.

**【Q&A Key Highlights】**
- **Distributor Productivity**: New partners can become productive in days to months, depending on market approvals and RSM support. Established relationships contribute 2-3x faster than new signings.
- **OpEx Cadence**: Surgical segment operating leverage expected to continue, with THP spending constrained to $5.5-$6.5 million in H2. No material tariff impacts anticipated in 2025.
- **THP Strategy**: Evaluation of partnerships with payers, providers, and product companies to accelerate growth. Potential milestones for OsStic launch in Q1 2027 remain on track.


Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript

- **26% Revenue Growth**: Sanara Surgical segment delivered $23.4 million in Q1 2025, driven by 28% jump in soft tissue repair products.
- **Margin Expansion**: Gross margin improved 240bps to 92%, with adjusted EBITDA up 125% YoY to $2.7 million.
- **Tissue Health Plus Launch**: Pilot program set for Q2, with metrics focused on clinician efficiency and workflow improvements.
- **Financial Flexibility**: $20.7 million cash balance and $12.25 million available under amended debt facility support growth initiatives.

**【CEO Summary Section】**
- Q1 2025 net revenue for Sanara Surgical reached $23.4 million, up 26% YoY, driven by 28% growth in soft tissue repair products to $20.5 million.
- Gross margin improved due to lower manufacturing costs, with Sanara Surgical segment adjusted EBITDA rising 125% YoY to $2.7 million.
- Tissue Health Plus segment preparing to launch pilot program with a wound care provider in Q2, with $7.5-$8.5 million in expected cash investment for the first half.

**【CFO Financial Commentary】**
- Q1 2025 gross profit increased 30% YoY to $21.6 million, with gross margin expanding 240bps to 92%.
- Operating expenses rose 30% YoY to $23.7 million, driven by $5.2 million increase in SG&A (including $2.4 million in Sanara Surgical sales expenses).
- Net loss widened to $3.5 million ($0.41/diluted share) vs. $1.8 million ($0.21) last year, due to higher interest expenses and Tissue Health Plus investments.
- Cash balance of $20.7 million as of March 31, with $12.25 million available under amended debt facility.

**【Commercial Execution Highlights】**
- Sanara Surgical distributor network expanded to 400+ partners (vs. 250+ in Q1 2024), with products sold in 1,300+ healthcare facilities.
- Surgeon penetration rates remain low, with significant opportunity to increase product adoption within existing facilities.
- Tissue Health Plus CoPilot platform launched in Q2, integrating clinical decision support and administrative automation tools.

**【Q&A Key Questions】**
- **Gross Margin Outlook**: CEO expects current margin levels to persist, with limited additional leverage from scaling.
- **Tissue Health Plus Pilot Success Metrics**: Focused on clinician protocol adherence, documentation efficiency, and staff productivity improvements.
- **Reorder Rates**: Anecdotally strong, with surgeons expanding product usage after successful initial cases.

Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

- **33% YoY revenue growth**: Driven by 39% expansion in self-tissue products and new distributor network.
- **Profitability improvement**: Sanara Surgical EBITDA up 73% to $9.1 million, offsetting THP investments.
- **OsStic breakthrough**: FDA-designated bone filler targeting 100K+ annual procedures, with U.S. launch in 2027.
- **THP pilot on track**: Q2 2025 launch with 6-state provider group, backed by $7.5-10M 2025 investment.
- **Financial strength**: $15.9M cash, new $55M debt facility, and narrowed net loss to $1.7M in Q4.


**【CEO Summary Section】**
- Full-year 2024 net revenue reached $86.7 million, up 33% YoY, driven by 39% growth in self-tissue products and 6% in bone fusion products.
- Adjusted EBITDA improved to $2.7 million (vs. -$0.1 million in 2023), with Sanara Surgical segment generating $9.1 million EBITDA (73% YoY increase).
- Ended 2024 with $15.9 million cash and $24.5 million borrowing capacity under a new $55M debt facility.
- Secured 11 new patents and two exclusive distribution agreements, including the ChemoMouthpiece.

**【CFO Financial Commentary】**
- Q4 2024 revenue rose 49% YoY to $26.3 million, with 56% growth in soft tissue repair products ($23.5M) and 8% in bone fusion ($2.8M).
- Gross margin expanded 160bps to 91.4%, fueled by higher-margin soft tissue sales.
- Operating expenses increased 51% to $24.4 million, driven by SG&A (+37%) and R&D (+270%).
- Net loss narrowed to $1.7 million (vs. $0.3 million), with Sanara Surgical segment profitable ($0.9M net income).
- 2025 Tissue Health Plus investment expected to be $7.5-10M, offset by surgical segment cash generation.

**【Commercial Progress (Seth Yon)】**
- Expanded distributor network to 350+ partners (from 250+ in 2023), covering 1,300+ facilities.
- Q4 2024 sales benefited from $1.8M Hurricane-related demand, but core growth remained strong.
- 2025 focus: add 10+ sales reps, expand distributor network, and penetrate new surgical accounts.

**【Tissue Health Plus Update (Sam Muppalla)】**
- Developed 35 clinical playbooks for chronic wounds and built tech platform for value-based care programs.
- Planning Q2 2025 pilot with a 6-state wound care provider group, targeting fee-for-service optimization.
- Recruited sales team and building BD pipeline for 2025 payer partnerships.

**【Strategic Partnership (Tyler Palmer)】**
- Exclusive U.S. rights to OsStic, a synthetic bone filler with FDA Breakthrough Device designation.
- OsStic addresses 100,000+ annual periarticular fractures, complementing existing bone fusion portfolio.
- Regulatory clearance expected Q1 2027, with U.S. launch targeting Q2 2027.

**【Q&A Highlights】**
- ChemoMouthpiece awaiting health econ study publication; targeting Q2 2025 commercial payor approvals.
- THP pilot success metrics: workflow integration, documentation quality, and reduced reimbursement risk.
- Actively pursuing financial partners to co-invest in THP commercialization.


Sanara MedTech (SMTI)-25 Mar 25-2024 Q4 Earnings call transcript

Sanara MedTech (SMTI)-13 Nov 24-2024 Q3 Earnings call transcript

Sanara MedTech Inc. (SMTI) Q1 2024 Earnings Call Transcript

Sanara MedTech (SMTI)-26 Mar 24-2023 Q4 Earnings call transcript

Sanara MedTech (SMTI)-14 Nov 23-2023 Q3 Earnings call transcript

- **Revenue Growth**: 63% YoY to $15.8 million, driven by expanded distribution and new product adoption.
- **Strategic Acquisitions**: $15.25M collagen assets acquisition eliminates $1.5M royalty, enabling cost savings and new product development.
- **Product Launches**: BIASURGE (mid-Q4) and Precision Imaging (FDA decision Q4) to address $1.5B surgical wound care market.
- **Operational Focus**: Hiring 20+ sales reps Q3-Q4 to capitalize on 3,000+ approved facilities; ALLOCYTE supply resolved Q3.
- **Financial Health**: $6.1M cash on hand; 63% revenue growth vs. 33% SG&A growth reflects operational efficiency.

**【Management Opening Remarks】**
- Q2 2023 revenue: $15.8 million (63% YoY growth), narrowing loss before tax to $1.9 million from $3.4 million in Q2 2022.
- BIASURGE Advanced Surgical Solution set for mid-Q4 launch; acquisition of collagen products business completed, eliminating $1.5 million annual royalty.

**【CEO Commentary】**
- Sales growth slowed due to delayed hiring in late 2022 and ALLOCYTE supply constraints; 1,200 new facilities approved via GPO, targeting 3,000+ facilities.
- Non-CellerateRX products (e.g., FORTIFY, TEXAGEN) drove $13.2 million in Q2 sales; BIASURGE expected to address $1.5 billion surgical wound care market.
- Acquisition of collagen assets includes 4 FDA-cleared products, 9 patents, and manufacturing control, reducing costs by ~30%.

**【CFO Financial Commentary】**
- Q2 2023 net revenue: $15.8 million (63% YoY growth); 6-month revenue: $31.3 million (79% YoY growth).
- SG&A expenses: $13.8 million (33% YoY growth); R&D: $1.2 million (8% YoY growth).
- Cash on hand: $6.1 million; $15.25 million paid for collagen assets, with $10 million earn-out potential.

**【Q&A Highlights】**
- **Scendia Sales**: Steady at $3 million/Q2, growth constrained by ALLOCYTE supply; resolution expected Q3.
- **Sales Penetration**: Same-facility sales growth driven by new product adoption; 1,200+ new facilities approved via GPO.
- **Precision Imaging**: FDA resubmission expected Q3, decision by end-2023; LFA approval discussions ongoing.
- **International Expansion**: Long-term opportunity, but priority on U.S. market penetration.
- **Value-Based Strategy**: 2024 launch target with InfuSystem; imager and LFA approvals critical for execution.

Actual		-0.16	-0.27	-0.48	-0.41	-0.42	-0.18	-0.01	-0.14	-0.22	-0.13	-0.03	-0.21	-0.41	-0.34	-0.18	-0.41	-0.23	-3.4	-0.19
Forecast		-0.12	-0.18	-0.27		-0.28	-0.32	-0.26	-0.33	-0.13	0	-0.13	-0.07	-0.21	-0.62	-0.115	-0.505	-0.44	-0.215	0.11
Surprise	0.00%	-33.33%	-50.00%	-77.78%	0.00%	-50.00%	+43.75%	+96.15%	+57.58%	-69.23%	0.00%	+76.92%	-200.00%	-95.24%	+45.16%	-56.52%	+18.81%	+47.73%	-1481.40%	-272.73%

SMTI

SMTI fundamentals

SMTI Q4 2025 Earnings

Earnings Call

You can ask Aime

SMTI

SMTI fundamentals

SMTI Q4 2025 Earnings

Earnings Call

SMTI Earnings Call Summary for Q4/20258:00 AM on Mar 24, 2026

SMTI Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

SMTI Earnings Call Summary for Q2/20258:00 AM on Aug 13, 2025

SMTI Earnings Call Summary for Q1/20258:00 AM on May 14, 2025

SMTI Earnings Call Summary for Q4/20248:00 AM on Mar 25, 2025

You can ask Aime